Feedback | Friday, November 22, 2024

  • Twitter
  • Facebook
  • YouTube
  • Instagram

August 1, 2024 5:23 PM

Lilly says weight loss drug cut heart failure risk by 38% in trial

Trial results show Eli Lilly's weight loss drug Zepbound reduces the risk of hospitalization, death and other outcomes for obese adults with a common type of heart failure, the company said on Thursday as it continues to build a case for the medication's wider health benefits. The drug, also known as tirzepatide, reduced the risk of a composite of heart failure urgent visit or hospitalization, oral diuretic intensification or cardiovascular death by 38% compared to a placebo. The trial enrolle...

Copyright © 2024 DD News. All rights reserved
Visitors: 11703236
Last Updated: 22nd Nov 2024